Business Context and Reporting Period
This Form 8-K was filed by Aquestive Therapeutics, Inc. on July 14, 2022. The report addresses a regulatory notice received from The Nasdaq Stock Market regarding the Company's compliance with listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance triggering the notice: the minimum bid price of the Company's common stock has been below $1.00 per share for 30 consecutive business days.
Material Changes
The material change reported is the receipt of a noncompliance notice from Nasdaq under Listing Rule 5450(a)(1) due to the sustained low stock price. This event has no immediate effect on the listing or trading of the Company's common stock on The Nasdaq Global Market.
Outlook, Risks, and Management Commentary
- Compliance Timeline: The Company has 180 calendar days, until January 10, 2023, to regain compliance.
- Compliance Requirement: The minimum bid price must meet or exceed $1.00 per share for a minimum of ten consecutive business days during the grace period.
- Contingency Plans: If compliance is not met by January 10, 2023, the Company may be eligible for an additional 180-day period if it transfers to The Nasdaq Capital Market, subject to meeting other listing standards.
- Delisting Risk: Failure to regain compliance by the end of the applicable period will result in delisting. The Company retains the right to appeal a delisting determination.
- Management Action: The Company intends to monitor the closing bid price and may consider a reverse stock split to regain compliance, though there is no assurance of success.
Investor Verification Checklist
- Verify the current trading price of AQST to assess the likelihood of meeting the $1.00 threshold within the 180-day window.
- Monitor for any future announcements regarding a reverse stock split or transfer to The Nasdaq Capital Market.
- Review the Company's market value of publicly held shares to determine eligibility for the Nasdaq Capital Market if the initial grace period expires.
- Check for any subsequent 8-K filings regarding the status of the compliance period or potential delisting appeals.